Merck & Co extends deadline for Vioxx product liability suits
US drug major Merck & Co says it has extended to June 30 the enrollment deadline for US eligible claimants with cases filed or tolled by November 9, 2007 wishing to be part of the program to resolve state and federal myocardial infarction and ischemic stroke claims resulting from use of the withdrawn arthritis painkiller Vioxx (rofecoxib) filed against the company in the USA (Marketletters passim).
The company formally extended the Walk Away Enrollment Deadline Date by which Merck could elect to terminate the resolution program to June 30; this action automatically extended the enrollment deadline to June 30.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze